Infliximab ELISA Kit

Produktnummer ABIN4886393

Human, Maus und Ratte Infliximab ELISA Kit, Colorimetric Assay für die Quantifizierung von Human, Maus und Ratte Infliximab.

Kurzübersicht für Infliximab ELISA Kit (ABIN4886393)

Target: Infliximab

Reaktivität: Human, Maus, Ratte

Nachweismethode: Colorimetric

Methodentyp: Sandwich ELISA

Detektionsbereich: 0.78 ng/mL - 25 ng/mL

Applikation: ELISA

Proben: Plasma, Serum

Produktdetails Infliximab ELISA Kit

Untere Nachweisgrenze: 0.78 ng/mL

Verwendungszweck: Quantification of Infliximab in biological matrices

Analytische Methode: Quantitative

Spezifität: Infliximab (Remicade)

Kreuzreaktivität (Details): hIgG1 and Infliximab prepared at 250 ng/ mL were assayed and exhibited no cross-reactivity or interference.

Bestandteile:

• Coated microtiter plate, 96 wells
• Calibrator diluent. - 1.8ml
• Calibrator 12ul 10X wash buffer - 25ml
• Assay buffer - 50ml
• 1000X detection reagent - 17ul TMB - 12ml
• TMB stop solution - 12ml
• Plate sealers - 3

Benötigtes Material:

• Precision pipettes calibrated to deliver 5-1000μL
• Multi-channel pipette calibrated to deliver 50-200μL
• Plate shaker
• Disposable tips
• Vortex-Mixe
• Distilled or de-ionized water
• Microplate reader capable of reading 450nm with background subtraction

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Probenmenge: 15 μL

Testdauer: 2.5 h

Plattentyp: Pre-coated

Protokoll: The Infliximab ELISA kit is designed to measure free Infliximab with high specificity and sensitivity . This assay employs the sandwich enzyme immunoassay technique. A precoated anti-Infliximab 96 well plate is provided. Calibrator, quality control samples and test samples are pipetted into the appropriate wells. Infliximab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Infliximab present in test samples and the concentration is calculated from the standard series.

Aufbereitung der Reagenzien:

Prepare the appropriate amount of required reagent on the day of use. Store all reagents as per instructions stated on the label. 1. Wash Buffer (1X) Preparation: Dilute wash buffer concentrate with ultra-pure water 1/10 before use (for example add 20 mL concentrate to 180 mL ultra-pure water). Mix well. 2. Detection Reagent (1X) Preparation: Dilute detection reagent with assay buffer 1/1000 before use (for example add 11 μL concentrate to 11 mL of assay buffer). Mix well. 3. Preparation of Calibrators: Prepare calibrators with concentrations ranging from 2,500 ng/mL to 78 ng/ mL. The following is an example calibrator curve.

Probennahme: This kit is compatible with EDTA-plasma, heparinplasma and serum samples. Samples can be stored at or below -20 °C for up to 1 year.

Aufbereitung der Proben:

Dilute calibrators and test samples 1/100 with assay buffer (for example add 5μL of prepared calibrator or sample to 495μL of assay buffer). Mix well. *Note that test samples may require further dilution when peak values are predicted to exceed 2.5 μg/mL. Do not store diluted samples.

Testdurchführung:

This assay employs the sandwich enzyme immunoassay technique. Anti- Infliximab is coated onto a 96 well microplate. Calibrator, quality control samples (if desired) and test samples are pipetted into the appropriate wells. Infliximab present in biological matrices is bound by the immobilized anti- Infliximab antibody. After washing away any unbound substances, enzyme linked anti- Infliximab antibody is added to the wells. This antibody is developed and purified specifically against truncated Remicade® (domain residing in Fc portion of the Remicade® molecule). The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Infliximab present in test samples. The color development is stopped and the intensity of the color is measured.

Ergebnisberechnung:

1. Construct a standard curve by plotting the absorbance obtained from each standard against concentration. Use a 4 or 5 parameter curve fit. Alternatively a log-log curve fit may be used. 2. The concentration of the unknowns can be read directly from this standard curve using the absorbance value for each sample. 3. Any sample undiluted or diluted still reading greater than the highest standard should be diluted appropriately with assay buffer and retested. If the samples have been diluted, the concentration determined from the standard curve must be multiplied by the dilution factor.

Testpräzision: Intra-assay precision: <10%
Inter-assay precision: <10%

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konservierungsmittel: Without preservative

Lagerung: -20 °C

Informationen zur Lagerung: -20C, 1 year

Haltbarkeit: 12 months

Details zu Infliximab

Target: Infliximab

Hintergrund: Infliximab (Remicade®) is a chimeric monoclonal antibody against tumour necrosis factor alpha (TNF- α). Infliximab neutralizes the biological activity of TNF- α by binding with high affinity to the soluble (free floating in the blood) and transmembrane (located on the outer membranes of T cells and similar immune cells) forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors.

Gen-ID: 7124